Premium
Maternal and neonatal elimination of amobarbital after treatment of the mother with barbiturates during late pregnancy
Author(s) -
Draffan G. H.,
Dollery C. T.,
Davies D. S.,
Krauer B.,
Williams F. M.,
Clare R. A.,
Trudinger B. J.,
Darling M.,
Sertel H.,
Hawkins D. F.
Publication year - 1976
Publication title -
clinical pharmacology and therapeutics
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.941
H-Index - 188
eISSN - 1532-6535
pISSN - 0009-9236
DOI - 10.1002/cpt1976193271
Subject(s) - amobarbital , phenobarbital , pregnancy , medicine , plasma levels , anesthesia , psychology , obstetrics , endocrinology , psychiatry , epilepsy , biology , genetics
Plasma half‐lives of amobarbital were determined in newborn children of 10 mothers who had been treated with barbiturates for hypertension in pregnancy for 6 to 42 days prior to delivery. Five mothers had received amobarbital, 200 mg daily, and 5, phenobarbital, 60 to 180 mg daily. Half‐lives in 7 of the babies ranged from 16.6 to 49.4 hr, comparable to those previously reported in babies of mothers who had received only a single dose of amobarbital. Thus there was no evidence of induction of amobarbital hydroxylation in these children. Two babies who had a greater than normal rise in serum bilirubin had longer half‐lives (86.1 and 117.7 hr). In 1 baby whose mother had membranous glomerulonephritis, plasma amobarbital concentration did not significantly change over the period of the study.